|
Adcirca (tadalafil) 20 mg tablets
|
60 per 30 days
|
40 mg per day
|
|
Adempas (riociguat) 0.5 mg tablets
|
90 per 30 days
|
The recommended starting dosage is 1 mg taken 3 times a day. For
patients who may not tolerate the hypotensive effect of Adempas,
consider a starting dose of 0.5 mg taken three times a day. If systolic
blood pressure remains greater than 95 mmHg and the patient has no
signs or symptoms of hypotension, up-titrate by 0.5 mg taken three times
a day. Dose increases should be no sooner than 2 weeks apart. The dose
can be increased to the highest tolerated dosage, up to a maximum of 2.5
mg taken 3 times per day. If at any time, the patient has symptoms of
hypotension, decrease the dosage by 0.5 mg taken three times per day.
|
|
Adempas (riociguat) 1 mg tablets
|
90 per 30 days
|
|
Adempas (riociguat) 1.5 mg tablets
|
90 per 30 days
|
|
Adempas (riociguat) 2 mg tablets
|
90 per 30 days
|
|
Adempas (riociguat) 2.5 mg tablets
|
90 per 30 days
|
|
Alyq (tadalafil) 20 mg tablets
|
60 per 30 days
|
40 mg per day
|
|
Letairis (ambrisentan) 5 mg tablets
|
30 per 30 days
|
Initiate treatment at 5 mg once daily with or without tadalafil 20 mg once
daily. At 4-week intervals, either the dose of Letairis or tadalafil can be
increased, as needed and tolerated, to Letairis 10 mg or tadalafil 40 mg.
|
|
Letairis (ambrisentan) 10 mg tablets
|
30 per 30 days
|
|
Liqrev (sildenafil) 10 mg/mL oral suspension
|
732 mL per 30 days
|
20 mg three times a day; may titrate to a maximum dose of 80 mg three
times a day
|
|
Opsumit (macitentan) 10 mg tablets
|
30 per 30 days
|
10 mg per day
|
|
Opsynvi(macitentan/tadalafil) 10 mg/20 mg tablets
|
30 per 30 days
|
Treatment-naïve to any PAH specific therapy or transitioning from
endothelin receptor antagonist (ERA) monotherapy: Initiate treatment at
one 10 mg/20 mg tablet once daily for one week. If tolerated, up titrate to one 10 mg/40 mg tablet once daily.
Transitioning from phosphodiesterase type 5 (PDE5) inhibitor
monotherapy or PDE5 inhibitor and ERA therapy in combination: One 10
mg/40 mg tablet once daily
|
|
Opsynvi (macitentan/tadalafil) 10 mg/40 mg tablets
|
30 per 30 days
|
|
Revatio (sildenafil) 10 mg/mL oral suspension
|
784 mL per 30 days
|
Patients ≥18 years of age: 20 mg three times a day; may be titrated to a
maximum dose of 80 mg three times a day
Patients 1 to 17 years of age:
• ≤20 kg: 10 mg three times a day
• >20 kg to <45 kg: 20 mg three times a day
• ≥45 kg: 20 mg three times a day; may be titrated to a maximum dose of
40 mg three times a day
|
|
Revatio (sildenafil) 20 mg tablets
|
360 per 30 days
|
|
Tadliq (tadalafil) 20 mg/5 mL oral suspension
|
300 mL per 30 days
|
40 mg (10 mL) per day
|
|
Tracleer (bosentan) 32 mg tablets for oral suspension
|
112 per 28 days
|
Patients >12 years of age and >40 kg: Initiate treatment at 62.5 mg twice
daily for 4 weeks and then increase to maintenance dose of 125 mg twice
daily.
Patients >12 years of age and <40 kg: Initial and maintenance dosing:
62.5 mg twice daily
Patients <12 years of age: Initial and maintenance dosing:
• >4-8 kg: 16 mg twice daily
• >8-16 kg: 32 mg twice daily
• >16-24 kg: 48 mg twice daily
• >24-40 kg: 64 mg twice daily
|
|
Tracleer (bosentan) 62.5 mg tablets
|
60 per 30 days
|
|
Tracleer (bosentan) 125 mg tablets
|
60 per 30 days
|
|
Tyvaso (treprostinil) 0.6 mg/mL inhalation solution
|
81.2 mL (28 ampules)
per 28 days
|
Up to 72 mcg four times a day
|
|
Tyvaso (treprostinil) DPI 16 mcg and 32 mcg
Inhalation Powder Titration Kit
|
1 kit (196 cartridges)
per 28 days
|
Initial dosage: One 16 mcg cartridge per treatment session, four times
daily.
Dosage should be increased by an additional 16 mcg per treatment
session at approximately 1- to 2- week intervals, if tolerated.
Titrate to target maintenance doses of 48 mcg to 64 mcg per treatment
session, four times daily.
If the prescribed dose is higher than 64 mcg per treatment session, more
than 1 cartridge will be needed per session.
|
|
Tyvaso (treprostinil) DPI 16 mcg, 32 mcg, and 48 mcg
Inhalation Powder Titration Kit
|
1 kit (252 cartridges)
per 28 days
|
|
Tyvaso (treprostinil) DPI 16 mcg Inhalation Powder
Maintenance Kit
|
1 kit (112 cartridges)
per 28 days
|
|
Tyvaso (treprostinil) DPI 32 mcg Inhalation Powder
Maintenance Kit
|
1 kit (112 cartridges)
per 28 days
|
|
Tyvaso (treprostinil) DPI 48 mcg Inhalation Powder
Maintenance Kit
|
1 kit (112 cartridges)
per 28 days
|
|
Tyvaso (treprostinil) DPI 64 mcg Inhalation Powder
Maintenance Kit
|
1 kit (112 cartridges)
per 28 days
|
|
Tyavso (treprostinil) DPI 32 mcg and 48 mcg
Inhalation Powder Maintenance Kit
|
1 kit (224 cartridges)
per 28 days
|
|
Uptravi (selexipag) 200 mcg tablets
|
140 per 28 days
|
Starting dose: 200 mcg twice daily. Increase the dose by 200 mcg twice
daily at weekly intervals to the highest tolerated dose up to 1600 mcg
twice daily.
|
|
Uptravi (selexipag) 400 mcg tablets
|
60 per 30 days
|
|
Uptravi (selexipag) 600 mcg tablets
|
60 per 30 days
|
|
Uptravi (selexipag) 800 mcg tablets
|
60 per 30 days
|
|
Uptravi (selexipag) 1000 mcg tablets
|
60 per 30 days
|
|
Uptravi (selexipag) 1200 mcg tablets
|
60 per 30 days
|
|
Uptravi (selexipag) 1400 mcg tablets
|
60 per 30 days
|
|
Uptravi (selexipag) 1600 mcg tablets
|
60 per 30 days
|
|
Uptravi (selexipag) Titration Pack (200 mcg/800 mcg
tablets)
|
1 pack (140 of 200 mcg
tablets, 60 of 800 mcg
tablets) per 28 days
|
|
Ventavis (iloprost) 10 mcg/mL inhalation solution
|
270 ampules per 30 days
|
5 mcg up to nine times per day. The 20 mcg/mL concentration is intended
for patients who are maintained at the 5 mcg dose and who have
repeatedly experienced extended treatment times which could result in
incomplete dosing.
|
|
Ventavis (iloprost) 20 mcg/mL inhalation solution
|
270 ampules per 30 days
|
|
Winrevair (sotatercept-csrk) 45 mg kit (one 45 mg
single-dose vial)
|
1 kit (one vial) per 21 days
|
Administer once every 3 weeks. Start dosing at 0.3 mg/kg. Increase to the
target dose of 0.7 mg/kg. Continue treatment at 0.7 mg/kg every 3 weeks
unless dosage adjustments are required.
|
|
Winrevair (sotatercept-csrk) 60 mg kit (one 60 mg
single-dose vial)
|
1 kit (one vial) per 21 days
|
|
Winrevair (sotatercept-csrk) 90 mg kit (two 45 mg
single-dose vials)
|
1 kit (two vials)
per 21 days
|
|
Winrevair (sotatercept-csrk) 120 mg kit (two 60 mg
single-dose vials)
|
1 kit (two vials)
per 21 days
|
